JMPWA
VIRX

JP Morgan Private Wealth Advisors’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

JP Morgan Private Wealth Advisors’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-571
Closed -$8K – 1604
2020
Q1 		$8K Buy
+571
New +$12.4K ﹤0.01% 1410

Other funds holding VIRX

ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

JP Morgan Private Wealth Advisors's VIRX Position: Q2 2020 in Review

JP Morgan Private Wealth Advisors sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q2 2020, closing a stake of 571 shares — an estimated $8K sold.

JP Morgan Private Wealth Advisors first reported a position in VIRX in Q1 2020 and held it in 1 quarter. The position peaked at $8K in Q1 2020. 41 funds tracked by Wall St. Rank hold VIRX as of Q2 2020.

  • JP Morgan Private Wealth Advisors reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • JP Morgan Private Wealth Advisors sold 571 Viracta Therapeutics, Inc. Common Stock shares in Q2 2020, an estimated $8K.
  • JP Morgan Private Wealth Advisors first reported a position in Viracta Therapeutics, Inc. Common Stock in Q1 2020 and held it in 1 quarter.
  • JP Morgan Private Wealth Advisors's Viracta Therapeutics, Inc. Common Stock position peaked at $8K in Q1 2020.
  • 41 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q2 2020.

Based on JP Morgan Private Wealth Advisors's 13F filing for Q2 2020, filed 13 Aug 2020.